KB
Kuldeep Bansal
About Kuldeep Bansal
Data last updated:
Kuldeep Bansal is a Director at Riozen Pharmaceutical Private Limited (since 2016). The companies operate in Pharma and Infrastructure and Utilities. Riozen Pharmaceutical Private Limited reported revenue of ₹47,039 (FY 2024). Earlier, Kuldeep Bansal was a Director at Bansal Infraprojects Private Limited (2016–2017).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 02 Nov 2016 | 2016 | ₹47,039 (FY 2024) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 01 Oct 2016 | 2010 | ₹218 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Kuldeep Bansal
| Name | DIN | Company | Designation |
|---|---|---|---|
| Jagdeep Bansal | 00698149 | Riozen Pharmaceutical Private Limited | Director |
| Rajesh Kumar Patra | 07623232 | Riozen Pharmaceutical Private Limited | Director |
| Smita Samal | 07623048 | Riozen Pharmaceutical Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Kuldeep Bansal
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kuldeep Bansal
Kuldeep Bansal currently holds 1 directorship: Riozen Pharmaceutical Private Limited (Director, since 02 Nov 2016, revenue ₹47,039 (FY 2024)).
Kuldeep Bansal was first appointed on 01 Oct 2016 as Director at Bansal Infraprojects Private Limited.
Kuldeep Bansal held 1 earlier board appointment: Bansal Infraprojects Private Limited (Director, 01 Oct 2016 to 12 Aug 2017).
The current boards of Kuldeep Bansal's companies include Jagdeep Bansal (Riozen Pharmaceutical Private Limited), Rajesh Kumar Patra (Riozen Pharmaceutical Private Limited), Smita Samal (Riozen Pharmaceutical Private Limited).